(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 8.59% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Catalyst Pharmaceuticals's revenue in 2026 is $588,989,000.On average, 9 Wall Street analysts forecast CPRX's revenue for 2026 to be $77,685,445,090, with the lowest CPRX revenue forecast at $72,000,578,290, and the highest CPRX revenue forecast at $82,033,055,360. On average, 9 Wall Street analysts forecast CPRX's revenue for 2027 to be $85,276,665,720, with the lowest CPRX revenue forecast at $76,675,480,569, and the highest CPRX revenue forecast at $93,339,284,541.
In 2028, CPRX is forecast to generate $91,890,895,277 in revenue, with the lowest revenue forecast at $84,189,763,152 and the highest revenue forecast at $106,008,416,267.